{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:19:14Z","timestamp":1781828354543,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T00:00:00Z","timestamp":1499904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00520-017-3802-9","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T03:46:21Z","timestamp":1499917581000},"page":"3017-3030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Supportive care for patients undergoing immunotherapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Bernardo Leon","family":"Rapoport","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronwyn","family":"van Eeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Klastersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devan","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"key":"3802_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","volume":"121","author":"K Ryungsa","year":"2007","unstructured":"Ryungsa K, Manabu E, Kazuak T (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1\u201314","journal-title":"Immunology"},{"key":"3802_CR2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","volume":"26","author":"T Chen","year":"2015","unstructured":"Chen T, Razak A, Bedard P et al (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26:1824\u20131829","journal-title":"Ann Oncol"},{"key":"3802_CR3","unstructured":"CTCAE v4.0 (2010) https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf . Last accesed the 03 Jan 2017"},{"issue":"211","key":"3802_CR4","first-page":"1","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13(211):1\u201314","journal-title":"BMC Med"},{"key":"3802_CR5","doi-asserted-by":"crossref","unstructured":"Tarhini A (2013) Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management, Scientifica (Cairo). No 857519","DOI":"10.1155\/2013\/857519"},{"key":"3802_CR6","first-page":"14","volume":"6","author":"JM Redman","year":"2016","unstructured":"Redman JM, Gibney GT, Atkins MB (2016) Advances in immunotherapy for melanoma. BMC Med 6:14\u201320","journal-title":"BMC Med"},{"key":"3802_CR7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/atm.2016.06.29","volume":"14","author":"M Tsiatas","year":"2016","unstructured":"Tsiatas M, Grivas P (2016) Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med 14:270","journal-title":"Ann Transl Med"},{"key":"3802_CR8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"3802_CR9","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.14694\/EdBook_AM.2015.35.76","volume":"35","author":"MA Postow","year":"2015","unstructured":"Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35:2092\u20132099","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3802_CR10","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD-1 and anti PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375\u20132391","journal-title":"Ann Oncol"},{"key":"3802_CR11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","volume":"60","author":"VR Belum","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA et al (2016) Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12\u201325","journal-title":"Eur J Cancer"},{"key":"3802_CR12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin J, Lao CD, Urba WJ et al (2015) Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 1:433\u2013440","journal-title":"JAMA Oncol"},{"key":"3802_CR13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330","journal-title":"N Engl J Med"},{"key":"3802_CR14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"key":"3802_CR15","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"issue":"8","key":"3802_CR16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","volume":"34","author":"DF McDermott","year":"2016","unstructured":"McDermott DF, Sosman JA, Sznol M et al (2016) Atelizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34(8):833\u2013842","journal-title":"J Clin Oncol"},{"key":"3802_CR17","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206\u20131212","journal-title":"JAMA Dermatol"},{"key":"3802_CR18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45\u201351","journal-title":"JAMA Dermatol"},{"key":"3802_CR19","first-page":"1340","volume":"9","author":"JA Lo","year":"2015","unstructured":"Lo JA, Fisher DE, Flaherty KT (2015) Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol 9:1340\u20131341","journal-title":"JAMA Oncol"},{"key":"3802_CR20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122\u2013133","journal-title":"N Engl J Med"},{"key":"3802_CR21","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006\u20132017","journal-title":"N Engl J Med"},{"key":"3802_CR22","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","volume":"69","author":"K Minkis","year":"2013","unstructured":"Minkis K, Garden BC, Wu S et al (2013) The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 69:e121\u2013e128","journal-title":"J Am Acad Dermatol"},{"key":"3802_CR23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","volume":"28","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Meyer N, Lamant L et al (2016) Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28:254\u2013263","journal-title":"Curr Opin Oncol"},{"key":"3802_CR24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","volume":"43","author":"KB Scheberg","year":"2016","unstructured":"Scheberg KB, Novoa RA, Wakelee HA et al (2016) Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 43:339\u2013346","journal-title":"J Cutan Pathol"},{"key":"3802_CR25","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S et al (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 152:1128\u20131136","journal-title":"JAMA Dermatol"},{"key":"3802_CR26","doi-asserted-by":"publisher","unstructured":"Bonigen J, Raynaud-Donzel C, Hureaux J et al (2016) Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol. doi: 10.1111\/jdv.14011","DOI":"10.1111\/jdv.14011"},{"key":"3802_CR27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA et al (2016) Ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. JAMA Oncol 2:234\u2013240","journal-title":"JAMA Oncol"},{"key":"3802_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00520-014-2434-6","volume":"23","author":"LK Jackson","year":"2015","unstructured":"Jackson LK, Johnson DB, Sosman JA et al (2015) Oral health in oncology: impact of immunotherapy. Support Care 23:1\u20133","journal-title":"Support Care"},{"key":"3802_CR29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319","journal-title":"N Engl J Med"},{"key":"3802_CR30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small cell cancer. N Engl J Med 373:123\u2013135","journal-title":"N Engl J Med"},{"key":"3802_CR31","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00520-016-3083-8","volume":"24","author":"JB Epstein","year":"2016","unstructured":"Epstein JB, Smutzer G, Doty RL (2016) Understanding the impact of taste changes in oncology care. Support Care Cancer 24:1917\u20131931","journal-title":"Support Care Cancer"},{"key":"3802_CR32","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00520-014-2503-x","volume":"23","author":"S Elad","year":"2015","unstructured":"Elad S, Jensen SB, Raber-Durlacher JE et al (2015) Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers. Support Care Cancer 23:1615\u20131622","journal-title":"Support Care Cancer"},{"key":"3802_CR33","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s00520-013-1871-y","volume":"21","author":"DP Saunders","year":"2013","unstructured":"Saunders DP, Epstein JB, Elad SA et al (2013) For the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer\/International Society of Oral Oncology (MASCC\/ISOO). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer 21:3191\u20133207","journal-title":"Support Care Cancer"},{"key":"3802_CR34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00520-014-2378-x","volume":"23","author":"S Elad","year":"2015","unstructured":"Elad S, Raber-Durlacher JE, Brennan MT et al (2015) Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer\/International Society of Oral Oncology (MASCC\/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer 23:223\u2013236","journal-title":"Support Care Cancer"},{"key":"3802_CR35","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1200\/JCO.2013.53.2630","volume":"32","author":"JL Leenstra","year":"2014","unstructured":"Leenstra JL, Miller RC, Qin R et al (2014) Doxepin rinse versus placebo in the treatment of acute mucositis pain. J Clin Oncol 32:1571\u20131577","journal-title":"J Clin Oncol"},{"issue":"8","key":"3802_CR36","first-page":"600","volume":"36","author":"JB Epstein","year":"2015","unstructured":"Epstein JB, Beier JS (2015) Management of hyposalivation and xerostomia: criteria for treatment strategies. Compend Contin Educ Dent 36(8):600\u2013603","journal-title":"Compend Contin Educ Dent"},{"key":"3802_CR37","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.oraloncology.2015.06.009","volume":"51","author":"J Deng","year":"2015","unstructured":"Deng J, Jackson L, Epstein JB et al (2015) Dental demineralization and caries in patients with head and neck cancer. Oral Oncol 51:824\u2013831","journal-title":"Oral Oncol"},{"key":"3802_CR38","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s00520-015-2827-1","volume":"23","author":"T Thorne","year":"2015","unstructured":"Thorne T, Olson K, Wismer W (2015) A state-of-the-art review of the management and treatment of taste and smell alterations in adult cancer patietns. Support Care Cancer 23:2843\u20132851","journal-title":"Support Care Cancer"},{"key":"3802_CR39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","volume":"4","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Schindler K, Querfeld C et al (2016) Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4:383\u2013389","journal-title":"Cancer Immunol Res"},{"key":"3802_CR40","first-page":"12691","volume":"30","author":"J Weber","year":"2015","unstructured":"Weber J, Kahler K, Hauschild A (2015) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:12691\u201312697","journal-title":"J Clin Oncol"},{"issue":"10","key":"3802_CR41","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2(10):1346\u20131353","journal-title":"JAMA Oncol"},{"key":"3802_CR42","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","volume":"119","author":"J Weber","year":"2013","unstructured":"Weber J, Dummer R, de Pril V et al (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:1675\u20131682","journal-title":"Cancer"},{"key":"3802_CR43","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1038\/cti.2014.18","volume":"3","author":"J Liu","year":"2014","unstructured":"Liu J, Blake S, Smyth R et al (2014) Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunol 3:e22","journal-title":"Clin Transl Immunol"},{"key":"3802_CR44","first-page":"560","volume":"4","author":"J Villadolid","year":"2015","unstructured":"Villadolid J, Amin A (2015) Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4:560\u2013575","journal-title":"Transl Lung Cancer Res"},{"key":"3802_CR45","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","volume":"197","author":"Y Bronstein","year":"2011","unstructured":"Bronstein Y, Ng C, Hwu P et al (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992\u2013W1000","journal-title":"AJR Am J Roentgenol"},{"key":"3802_CR46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"3802_CR47","unstructured":"Yervoy (ipilimumab) (2103) Princeton, NJ: Bristol-Myers Squibb (package insert)"},{"key":"3802_CR48","first-page":"30","volume":"28","author":"B Teply","year":"2014","unstructured":"Teply B, Lipson E (2014) Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) 28:30\u201338","journal-title":"Oncology (Williston Park)"},{"key":"3802_CR49","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517\u20132526","journal-title":"N Engl J Med"},{"key":"3802_CR50","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.2147\/DDDT.S115493","volume":"10","author":"X Zhang","year":"2016","unstructured":"Zhang X, Ran Y, Wang K et al (2016) Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Des Devel Ther 10:3153\u20133161","journal-title":"Drug Des Devel Ther"},{"key":"3802_CR51","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jgh.12888","volume":"30","author":"R Cheng","year":"2015","unstructured":"Cheng R, Cooper A, Kench J et al (2015) Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30:657\u2013666","journal-title":"J Gastroenterol Hepatol"},{"key":"3802_CR52","doi-asserted-by":"crossref","unstructured":"Tokudome T (2016) Anti-CTLA-4 antibodies immunotherapy of cancer. Edited by Yoshiyuki Yamaguchi. Chapter 18, pp263\u2013282, Springer","DOI":"10.1007\/978-4-431-55031-0_18"},{"key":"3802_CR53","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/imt-2016-0029","volume":"8","author":"HR Kourie","year":"2016","unstructured":"Kourie HR, Klastersky J (2016) Immune checkpoint inhibitors: side effect and management. Immunotherapy 8:799\u2013807","journal-title":"Immunotherapy"},{"key":"3802_CR54","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 anti-body in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"3802_CR55","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","volume":"27","author":"MR Robinson","year":"2004","unstructured":"Robinson MR, Chan CC, Yang JC et al (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27:478\u2013479","journal-title":"J Immunother"},{"key":"3802_CR56","unstructured":"Postow M, Wolchok J (2016) Toxicities associated with checkpoint inhibitor immunotherapy. Uptodate http:\/\/www.uptodate.com\/contents\/toxicities-associated-with-checkpoint-inhibitor-immunotherapy . (Last accessed 30 Nov 2016)"},{"key":"3802_CR57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","volume":"164","author":"L Min","year":"2011","unstructured":"Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164:303\u2013307","journal-title":"Eur J Endocrinol"},{"key":"3802_CR58","first-page":"69","volume":"7","author":"T Hager","year":"2014","unstructured":"Hager T, Seitz B (2014) Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 7:69\u201377","journal-title":"Onco Targets Ther"},{"key":"3802_CR59","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/15569527.2013.781618","volume":"32","author":"BS Modjtahedi","year":"2013","unstructured":"Modjtahedi BS, Maibach H, Park S (2013) Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol 32:341\u2013343","journal-title":"Cutan Ocul Toxicol"},{"key":"3802_CR60","doi-asserted-by":"publisher","unstructured":"Spain L, Walls G, Julve M, et al (2016) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature, Ann Oncol. Published online October 25, 2016. 10.1093\/annonc\/mdw558","DOI":"10.1093\/annonc\/mdw558"},{"key":"3802_CR61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C et al (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology 16:589\u2013593","journal-title":"Neuro-Oncology"},{"issue":"240","key":"3802_CR62","first-page":"1","volume":"8","author":"E Simeone","year":"2014","unstructured":"Simeone E, Grimaldi AM, Esposito A et al (2014) Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 8(240):1\u20135","journal-title":"J Med Case Rep"},{"key":"3802_CR63","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","volume":"32","author":"M Akhtari","year":"2009","unstructured":"Akhtari M, Waller EK, Jaye DL et al (2009) Neutropnia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 32:322\u2013324","journal-title":"J Immunother"},{"key":"3802_CR64","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMc1509362","volume":"374","author":"R Nair","year":"2016","unstructured":"Nair R, Gheith S, Nair S et al (2016) Immunotherapy-associated hemolytic anemia with pure red-cell aplasia. N Engl J Med 374:1096\u20131097","journal-title":"N Engl J Med"},{"key":"3802_CR65","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638\u2013647","journal-title":"Kidney Int"},{"key":"3802_CR66","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","volume":"9","author":"N Murakami","year":"2016","unstructured":"Murakami N, Borges TJ, Yamashita M et al (2016) Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J 9:411\u2013417","journal-title":"Clin Kidney J"},{"key":"3802_CR67","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","volume":"58","author":"AM Giacomo Di","year":"2009","unstructured":"Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297\u20131306","journal-title":"Cancer Immunol Immunother"},{"key":"3802_CR68","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749\u20131755","journal-title":"N Engl J Med"},{"key":"3802_CR69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000447053","volume":"136","author":"I Kushnir","year":"2017","unstructured":"Kushnir I, Wolf I (2017) Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology 136:49\u201351","journal-title":"Cardiology"},{"key":"3802_CR70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50","journal-title":"J Immunother Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3802-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3802-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3802-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T05:11:01Z","timestamp":1602479461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3802-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["3802"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3802-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}